Effects of metformin therapy on malondialdehyde level and paraoxonase 1 activitiy in patients with polycystic ovary syndrome
1Department of Biochemistry Erciyes University, Medical Faculty Kayseri, Turkey
2Department of Endocrinology, Erciyes University Medical Faculty, Kayseri, Turkey
J Clin Pract Res 2008; 30(2): 65-70
Full Text PDF

Abstract

Purpose: The aim of this study was to assess the effects of metformin on oxidative stress that may increase the risk of cardiovascular disease in patients with polycystic ovary syndrome.
Materials and methods: Fifteen patients with polycystic ovary syndrome and 17 healthy subjects were included in this study. Patients were treated with 2x850 mg/day metformin for six months. Serum androgen and malondialdehyde levels and paraoxonase 1 activity levels were measured in serum obtained from study groups.
Results: Significantly decreased paraoxonase 1 activities, but increased free testosterone, dihydroepyandrostenedione sulfate and Malondialdehyde levels were found in patients with polycystic ovary syndrome compared to those of controls. Paraoxonase 1 activities increased and Malondialdehyde levels decreased significantly after metformin therapy (p<0.05).
Conclusions: Increased reactive oxygen species levels in patients with polycystic ovary syndrome might result in decreasing antioxidant paraoxonase 1 activity and increasing Malondialdehyde levels. Metformin therapy may inhibit the risk of cardiovascular diseases by decreasing lipid peroxidation and increasing paraoxonase 1 activity.


Polikistik Over Sendromlu Hastalarda, Metformin Tedavisinin Malondialdehid Düzeyi ile Paraoksonaz 1 Aktivitesi Üzerine Etkisi
1Department of Biochemistry Erciyes University, Medical Faculty Kayseri, Turkey
2Department of Endocrinology, Erciyes University Medical Faculty, Kayseri, Turkey
Journal of Clinical Practice and Research 2008; 2(30): 65-70

Amaç: Bu çalışmanın amacı, metformin tedavisinin, polikistik over sendromlu hastalarda kardiovasküler hastalık riskini artıran oksidatif stres üzerine etkilerini araştırmaktır.
Gereç ve Yöntem: Bu çalışmaya, 15 polikistik over sendromlu hasta ve 17 sağlıklı birey dahil edildi. Hasta grubuna altı ay süreyle, 2x850 mg/gün metformin tedavisi verildi. Çalışma gruplarından elde edilen serum örneklerinde serum androjen ve malondialdehid seviyeleri ve paraoksonaz 1 aktivitesi ölçüldü.
Bulgular: Polikistik over sendromlu hastalarda kontrol grubuna göre, paraoksonaz 1 aktivitesi anlamlı şekilde düşük; serum androjen ve malondialdehid seviyeleri ise anlamlı şekilde yüksek bulundu. Metformin tedavisinden sonra, paraoksonaz 1 aktivitesinde anlamlı artış; serbest testosteron, dihidroepiandrostenedion sülfat ve malondialdehid seviyesinde ise anlamlı azalma görüldü (p<0.05).
Sonuç: Polikistik over sendromlu hastalarda artmış reaktif oksijen türlerinin, paraoksonaz 1 aktivitesini azaltabileceği, malondialdehid düzeylerini ise yükseltebileceği tespit edildi. Bu hastalara uygulanan metformin tedavisinin, lipid peroksidasyonunu azaltıp, serum paraoksonaz 1 aktivitesini yükselterek, kardiovasküler riski artıran oksidatif stresi önleyebileceği düşünüldü.